PMDI (Psychemedics) EBIT: $-1.89 Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMDI Psychemedics Corp PMDI
58 GF Score
Price $2.49
View Full Analysis

What is Psychemedics EBIT?

Psychemedics PMDI +13.18% 58 EBIT is $-1.89 Mil as of Dec. 2024. GuruFocus rates PMDI with a GF Score™ of 58/100.

Psychemedics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was $0.17 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Psychemedics's annualized ROC % for the quarter that ended in Dec. 2024 was 12.40%. Psychemedics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 14.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Psychemedics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -12.63%.

Psychemedics  (OTCPK:PMDI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Psychemedics's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=0.672 * ( 1 - 0% )/( (5.62 + 5.218)/ 2 )
=0.672/5.419
=12.40 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=9.835 - 2.81 - ( 1.405 - max(0, 3.793 - 6.047+1.405))
=5.62

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.318 - 1.683 - ( 1.417 - max(0, 2.711 - 4.938+1.417))
=5.218

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Psychemedics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.684/( ( (3.195 + max(1.817, 0)) + (2.925 + max(1.475, 0)) )/ 2 )
=0.684/( ( 5.012 + 4.4 )/ 2 )
=0.684/4.706
=14.53 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.325 + 0 + 1.302) - (2.81 + 0 + 0)
=1.817

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.5 + 0 + 0.997) - (1.683 + 0 + 0.339)
=1.475

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Psychemedics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-1.89/14.962
=-12.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psychemedics EBIT Related Terms

Psychemedics EBIT Historical Data

* Premium members only.

The historical data trend for Psychemedics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psychemedics EBIT Chart

Psychemedics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.07 0.21 -1.08 -3.42 -1.89

Psychemedics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -0.57 -0.90 -0.60 0.17

PMDI vs MBAI, MYNZ, ADVB: EBIT Comparison

For the Diagnostics & Research subindustry, Psychemedics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psychemedics EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Psychemedics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Psychemedics's EV-to-EBIT falls into.


PMDI
58GF Score
Psychemedics Corp PMDI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psychemedics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-1.89 Mil mean?
Psychemedics (PMDI) has a EBIT of $-1.89 Mil as of Dec. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Psychemedics.
Is Psychemedics' EBIT too high?
Psychemedics' current EBIT is $-1.89 Mil. Overall, Psychemedics has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Psychemedics' EBIT compare to MBAI and MYNZ?
Psychemedics' EBIT of $-1.89 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Psychemedics. Psychemedics's current EBIT is $-1.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psychemedics stock overvalued right now?
Psychemedics (PMDI) has a current EBIT of $-1.89 Mil. The current EBIT is $-1.89 Mil. Psychemedics' overall GF Score™ is 58/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Psychemedics (PMDI), the current EBIT is $-1.89 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psychemedics Business Description

Address 5220 Spring Valley Road, Suite 230, Dallas, TX, USA, 75254
Psychemedics Corp provides testing services for the detection of drug abuse and other health markers through the analysis of hair samples. The company generates revenue mainly from providing drug and alcohol testing services for its customers for an agreed-upon fee per unit tested. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in it without destroying the drugs. Geographically, the majority of its revenue comes from the United States, and also has a presence in other markets.
58GF Score

Get the complete analysis for PMDI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.49
Price